US2017233486A1PendingUtilityA1

Polynucleotides encoding anti-notch1 nrr antibody polypeptides

55
Assignee: GENENTECH INCPriority: Jun 4, 2007Filed: Nov 22, 2016Published: Aug 17, 2017
Est. expiryJun 4, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Christian W. SiebelYan Wu
A61P 37/02A61P 37/06A61P 9/10A61P 37/00A61P 37/08A61P 43/00A61P 35/02A61P 9/00A61P 3/10A61P 25/28A61P 25/00A61P 31/00A61P 29/00A61P 35/00A61P 21/00A61P 19/00C07K 2317/76C07K 16/18C07K 2317/73C12N 5/12C07K 2317/33C07K 2317/34A61K 2039/505C07K 16/30C07K 2317/92C07K 2317/55C12N 15/09C12N 15/63C12N 5/10A61K 39/3955C07K 2317/565C07K 16/2863C12N 2330/50C07K 14/705C07K 2317/56C07K 16/3015A61K 45/06C07K 2317/567C07K 2317/14C07K 16/28C07K 14/71
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.

Claims

exact text as granted — not AI-modified
1 . to  104 . (canceled) 
     
     
         105 . A polynucleotide encoding:
 (a) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 comprising, in order, SEQ ID NO:7, 8, and 9; or   (b) a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 comprising, in order, SEQ ID NO:1, 2, and 6; or   (c) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NOs:7, 8, 9, 1, 2, and 6.   
     
     
         106 . A polynucleotide encoding:
 (a) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 comprising, in order, SEQ ID NO:7, 8, and 10; or   (b) a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 comprising, in order, SEQ ID NO:1, 3, and 6; or   (c) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 10, 1, 3, and 6.   
     
     
         107 . A polynucleotide encoding:
 (a) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 comprising, in order, SEQ ID NO:7, 8, 11; or   (b) a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 comprising, in order, SEQ ID NO:1, 4, 6; or   (c) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 11, 1, 4, 6.   
     
     
         108 . A polynucleotide encoding:
 (a) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 comprising, in order, SEQ ID NO:7, 8, 12; or   (b) a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 comprising, in order, SEQ ID NO:1, 5, 6; or   (c) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 12, 1, 5, 6.   
     
     
         109 . An expression vector comprising the polynucleotide of  claim 105 . 
     
     
         110 . An expression vector comprising the polynucleotide of  claim 106 . 
     
     
         111 . An expression vector comprising the polynucleotide of  claim 107 . 
     
     
         112 . An expression vector comprising the polynucleotide of  claim 108 . 
     
     
         113 . A host cell comprising the polynucleotide of  claim 105 , wherein the polynucleotide encodes a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NOs:7, 8, 9, 1, 2, and 6. 
     
     
         114 . A host cell comprising the polynucleotide of  claim 106 , wherein the polynucleotide encodes a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 10, 1, 3, 6. 
     
     
         115 . A host cell comprising the polynucleotide of  claim 107 , wherein the polynucleotide encodes a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 11, 1, 4, 6. 
     
     
         116 . A host cell comprising the polynucleotide of  claim 108 , wherein the polynucleotide encodes a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NO:7, 8, 12, 1, 5, 6. 
     
     
         117 . The host cell of  claim 113 , which is a prokaryotic host cell. 
     
     
         118 . The host cell of  claim 113 , which is a eukaryotic host cell. 
     
     
         119 . The host cell of  claim 118 , which is a mammalian host cell. 
     
     
         120 . The host cell of  claim 114 , which is a prokaryotic host cell. 
     
     
         121 . The host cell of  claim 114 , which is a eukaryotic host cell. 
     
     
         122 . The host cell of  claim 121 , which is a mammalian host cell. 
     
     
         123 . The host cell of  claim 115 , which is a prokaryotic host cell. 
     
     
         124 . The host cell of  claim 115 , which is a eukaryotic host cell. 
     
     
         125 . The host cell of  claim 124 , which is a mammalian host cell. 
     
     
         126 . The host cell of  claim 116 , which is a prokaryotic host cell. 
     
     
         127 . The host cell of  claim 116 , which is a eukaryotic host cell. 
     
     
         128 . The host cell of  claim 127 , which is a mammalian host cell. 
     
     
         129 . A method of producing an anti-Notch1 NRR antibody, said method comprising (a) culturing the host cell of  claim 113  such that the antibody is expressed, and (b) recovering the antibody. 
     
     
         130 . The method of  claim 129 , wherein the host cell is a prokaryotic host cell. 
     
     
         131 . The method of  claim 129 , wherein the host cell is a eukaryotic host cell. 
     
     
         132 . The method of  claim 131 , wherein the host cell is a mammalian host cell. 
     
     
         133 . A method of producing an anti-Notch1 NRR antibody, said method comprising (a) culturing the host cell of  claim 114  such that the antibody is expressed, and (b) recovering the antibody. 
     
     
         134 . The method of  claim 132 , wherein the host cell is a prokaryotic host cell. 
     
     
         135 . The method of  claim 132 , wherein the host cell is a eukaryotic host cell. 
     
     
         136 . The method of  claim 135 , wherein the host cell is a mammalian host cell. 
     
     
         137 . A method of producing an anti-Notch1 NRR antibody, said method comprising (a)culturing the host cell of  claim 115  such that the antibody is expressed, and (b) recovering the antibody. 
     
     
         138 . The method of  claim 137 , wherein the host cell is a prokaryotic host cell. 
     
     
         139 . The method of  claim 137 , wherein the host cell is a eukaryotic host cell. 
     
     
         140 . The method of  claim 139 , wherein the host cell is a mammalian host cell. 
     
     
         141 . A method of producing an anti-Notch1 NRR antibody, said method comprising (a) culturing the host cell of  claim 116  such that the antibody is expressed, and (b) recovering the antibody. 
     
     
         142 . The method of  claim 141 , wherein the host cell is a prokaryotic host cell. 
     
     
         143 . The method of  claim 141 , wherein the host cell is a eukaryotic host cell. 
     
     
         144 . The method of  claim 143 , wherein the host cell is a mammalian host cell.

Join the waitlist — get patent alerts

Track US2017233486A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.